Article Text

other Versions

PDF
The Chemokine Receptor, CXCR4, Is Expressed in Pancreatic Intraepithelial Neoplasia
  1. Ryan M. Thomas (rthoma4{at}gmail.com)
  1. University of Cincinnati, United States
    1. Joseph Kim (jokim{at}coh.org)
    1. City of Hope Cancer Center, United States
      1. Monica P. Revelo-Penafiel (mprevelo{at}uc.edu)
      1. University of Cincinnati, United States
        1. Rita Angel (rita.angel{at}uc.edu)
        1. University of Cincinnati, United States
          1. David D. Dawson (ddawson{at}mednet.ucla.edu)
          1. University of California, los Angeles, United States
            1. Andrew M. Lowy (alowy{at}ucsd.edu)
            1. University of California, San Diego, United States

              Abstract

              Objective: The chemokine CXCL12, together with its specific receptor, CXCR4, have been shown to mediate invasiveness and metastatic behavior in pancreatic cancer cells. The expression of CXC12/CXCR4 has not been previously examined in pancreatic intraepithelial neoplasias (PanIN), the accepted precursor lesions to pancreatic duct cancer.

              Design: In this study we sought to characterize the expression of CXCL12 and CXCR4 during the progression of PanIN using both a murine model and human tissues.

              Results: These studies reveal that both CXCL12 and CXCR4 are expressed in PanIN and that the frequency increases during PanIN progression (0% CXCR4 expression in normal mouse and human ducts vs. 100% in mouse PanIN 3 and 77% in human PanIN 3). Next we demonstrate a dose-dependent increase in the proliferation of murine PanIN cells when exposed to CXCL12. Finally, we show that expression of CXCR4 in murine PanIN cells is partially dependent on MAPK signaling and that the effect of CXCL12 on PanIN proliferation can be abrogated by a MAPK inhibitor.

              Conclusions: Together these results demonstrate that CXCL12/CXCR4 expression begins in the pre-invasive stages of pancreatic neoplasia, and suggest that the presence of an autocrine loop that is at least partially regulated by MAPK signaling. Further studies that define the role of CXCR4 signaling in PanIN progression will determine if CXCR4 could serve as a novel target for chemoprevention and early stage therapy in pancreatic cancer.

              Statistics from Altmetric.com

              Request permissions

              If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.